For research use only. Not for therapeutic Use.
Memogain, also known as GLN-1062, is an acetylcholinesterase (AChE) inhibitor potentially for the treatment of Alzheimer/’s disease. Memogain, a pro-drug, liberates galantamine on cleavage by a carboxyesterase in the brain. Memogain has more than 15-fold higher bioavailability in the brain than the same doses of galantamine. In the brain, Memogain is enzymatically cleaved to galantamine, thereby regaining its pharmacological activity as a cholinergic enhancer.
| Catalog Number | I007950 |
| CAS Number | 224169-27-1 |
| Synonyms | Memogain; GLN-1062; GLN-1062; GLN-1062;(4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-yl benzoate |
| Molecular Formula | C24H25NO4 |
| Purity | ≥95% |
| Target | Acetylcholinesterase Inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| InChI | InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1 |
| InChIKey | JKVNJTYHRABHIY-WXVUKLJWSA-N |
| SMILES | CN1CC[C@]23C4=C(O[C@@]2([H])C[C@@H](OC(C5=CC=CC=C5)=O)C=C3)C(OC)=CC=C4C1 |
| Reference | </br>1:Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer/’s Disease Mice. Bhattacharya S, Maelicke A, Montag D.J Alzheimers Dis. 2015;46(1):123-36. doi: 10.3233/JAD-142421. PMID: 25720404 </br>2:Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK.J Mol Neurosci. 2010 Jan;40(1-2):135-7. doi: 10.1007/s12031-009-9269-5. Epub 2009 Aug 11. PMID: 19669943 |
